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Summary. Formerly known for its importance in the
immune system and kidney regeneration, it is becoming
more apparent that HAVcR-1 is an important protein in
cancer biology. HAVcR-1 is overexpressed in numerous
cancers and associates with critical molecules of tight
junctions. Tight junctions are critical in homeostasis of
cellular compartments via the maintenance of epithelia
and endothelia however it has also be suggested that via
the prevention of dissemination, intravasation and
extravasation, tight junctions play a critical role in the
prevention of cancer metastasis. HAVcR-1 shedding and
the production of the HAVcR-1 ectodomain has been
linked to increased IL-6 thus implicated it in the process
of angiogenesis via the activation of the STAT3 pathway
leading to increased HIF-1α. The HAVcR-1 ectodomain
has also been shown to be a potential urinary biomarker
in certain cancers. HAVcR-1 is potentially important
molecule both for the detection of cancer and the
treatment of cancer by being a novel target for anti-
cancer therapeutics. 
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Introduction
Cells are reliant on a wide array of transmembrane
proteins to respond to external signals and coordinate
cellular responses to these signals. The Hepatitis A virus
cellular receptor (HAVcR-1), also termed T-cell Ig and
mucin domain containing molecule 1 (TIM-1) and
kidney injury molecule 1 (KIM-1), is the cellular
receptor for Hepatocellular Piconavirus the cause of
acute hepatitis A in humans (Feigelstock et al., 1998).
HAVcR-1 is a class I integral membrane glycoprotein,
consisting of an N-terminal extracellular domain
containing a cystine rich region, displaying homology to
members of the immunoglobulin (Ig) superfamily,
followed by an extended mucin like O-glycosylated
threonine, serine and proline rich region, allowing
accessibility to interactions with extracellular proteins
(Kaplan et al., 1996). 
As well as in hepatitis A, HAVcR-1 has been
implicated in numerous other diseases. Although
expressed on every tested human organ including: liver,
small intestine, colon and spleen as well as high
expression on the kidney and testis, the natural function
of has not been fully investigated (Feigelstock et al.,
1998). However it has been shown to be important in;
the immune system whereby TIMs family of surface
receptors are thought to regulate both physiologic and
pathologic immune responses, in kidney repair whereby
HAVcR-1 regulates survival and regeneration of cells
and there is immerging evidence for HAVcR-1
importance in various cancers (Curtiss et al., 2011).
HAVcR-1 being overexpressed in numerous cancers
has led to investigations into its role in cancer
development (Vila et al., 2004). HAVcR-1 is involved in
tight junctions (TJ), which have an imperative role in
cell to cell adhesion to maintain distinct internal
compartments. They are also thought to be important
structure in cancer metastasis via the prevention of
cancer cell dissemination as well as intravasation and
extravasation. Thus the disruption of TJs has been linked
to cancer metastasis and evidence suggests HAVcR-1
overexpression is responsible for this disruption, thus
linking HAVcR-1 to cancer metastasis (Martin and
Review
HAVcR-1 involvement in cancer progression
Emily J.A. Telford, Wen G. Jiang and Tracey A. Martin
Cardiff China Medical Research Collaborative (CCMRC), (Cardiff University - Peking University Cancer Institute and Cardiff University
- Capital Medical University Joint Centre Biomedical Research), Cardiff University, School of Medicine, Ground Floor, Henry Welcome
Building, Heath Park, Cardiff, UK
Histol Histopathol (2017) 32: 121-128
http://www.hh.um.es
Offprint requests to: Tracey A. Martin, Cardiff China Medical Research
Collaborative (CCMRC) Cardiff University, School of Medicine, Ground
Floor, Henry Welcome Building, Heath Park, Cardiff CF14 4XN, UK. e-
mail: MartinTA1@cardiff.ac.uk
DoI: 10.14670/HH-11-817
Histology and
Histopathology
From Cell Biology to Tissue Engineering
Jiang, 2009). HAVcR-1 is also cleaved proximal to the
membrane releasing the HAVcR-1 ectodomain which
may have importance in: angiogenesis via the activation
of the IL-6/ STAT3 pathway leading to increased HIF-1α
and metastasis via the Ig-like domain mediating binding
to various cell types. Furthermore in urological cancers
the HAVcR-1 ectodomain is excreted into the urine
making it a possible biomarker (Han et al., 2005).
Therefore, due to its emerging importance, HAVcR-1 is
a molecule of interest in cancer research and may serve
as a novel target for anti-cancer therapeutics.
Structure of HAVcR-1
Human HAVcR-1 was identified due to its
homology to the simian HAVcR-1,a mucin-like class I
integral membrane glycoprotein, found due to
monoclonal antibodies giving African green monkey
kidney cells (AGMK) protection from hepatitis A
(Kaplan et al., 1996). Sequence analysis revealed that
HAVcR-1 is 359 amino acids long with 79.11%
homology to the simian counterpart (Feigelstock et al.,
1998). The gene encoding HAVcR-1 was first located in
mice to be on chromosome 11 then due to sequence
homology chromosome 5q31.1-32.3 in humans (Kaplan
et al., 1996). This gene is approximately 38.7kb and
consists of 9 exons and 8 introns (Fig. 1.A) (Vila et al.,
2004). 
Similarly with the simian HAVcR-1, the human form
has the key features of a type I intergral membrane
glycoprotein. Following the initial methionine at the N-
terminus there is a 17 amino acid signal sequence with a
hydrophobic core. The second distinctive hydrophobic
region and the major hydrophobic region of HAVcR-1 is
a 22 amino acid transmembrane domain (TMD) between
residues 290 to 311. There is a conserved Cys296 within
the TMD which may allow the addition of fatty acids to
aid in the stabilisation of membrane attachment. The
extracellular domain of HAVcR-1 exists between the
signalling sequence and TMD, it is 272 amino acids in
size and is comprised of two distinct regions; cystine
(Cys) rich region and threonine, serine and proline rich
region (Feigelstock et al., 1998). 
The Cys-rich region, also known as the
immunoglobulin (Ig) like domain, consisting of 109
amino acids, is the most homologous between simian
and human HAVcR-1, containing six conserved cys
residues and the first but not second N-glycosylation
sites (Feigelstock et al., 1998, Bailly et al., 2002). The
TSP rich region, also known as the mucin like domain,
of 163 amino acids lies between the cys-rich region and
TMD. Only 13 of the 27 consecutive repeats of the
consensus PTTTTL remain in the human HAVcR-1 TSP
rich region, but both N-glycosylation sites found in
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Fig. 1. HAVcR-1 gene,
structural domains, predicted
secondary structure and
cytoplasmic domain sequence.
Adapted from (Bailly et al.,
2002; Vila et al., 2004). 
A. Representation of the
HAVcR-1 gene showing the
size in base pairs of the
introns number 1- 8 and the
exons numbered in roman
numerals 1-9. 
B. Representation of HAVcR-
1b protein showing the size
and position of its structural
domains, position of cysteine
residues in the Ig-like domain
represented by C, position of
possible N-glycosylation sites
represented by triangles,
position of the tyrosine
phosphorylation motif
QAEDNIY represented by P
and predicted cleavage site
represented by a black box. 
C. Predicted secondary
structure of HAVcR-1. 
D. Amino acid sequence of the
cytoplasmic domain of
HAVcR-1a and HAVcR-1b.
simian HAVcR-1 are conserved as well as a third
possible N-glycosylation site located at residues 258 to
260 (Feigelstock et al., 1998). This TSP-rich region is
predicted to be heavily glycosylated and to have an
extended conformation, extending the cys-rich region
away from the cell membrane like a stalk (Jentoft, 1990;
Kuchroo et al., 2003). The intracellular domain of
human HAVcR-1 is 48 amino acids, 12 amino acids
shorter than that of the simian HAVcR-1, contains the
tyrosine phosphorylation motif QAENIY (Fig. 1A)
(Feigelstock et al., 1998; Bailly et al., 2002). Due to
homology human HAVcR-1 is predicted to have a
similar structure as simian HAVcR-1, known as the
lollipop on a stick model (Fig. 1C) (Jentoft, 1990).
A second homologue was also cloned from rat KIM-
1 termed HAVcR-1a (Ichimura et al., 1998). Thus the
simian cloned HAVcR-1 is termed HAVcR-1b. HAVcR-
1a was predicted to be 334 amino acids, showing 43.8%
homology to rat KIM-1 with the Ig-like domain being
the most homologous containing six conserved cystines.
It was also predicted that HAVcR-1a predominantly
exists on the apical membrane of epithelial cells
(Ichimura et al., 1998). HAVcR-1a is predominantly
expressed in the liver whereas HAVcR-1b is
predominantly expressed in the kidneys (Kuchroo et al.,
2003). HAVcR-1a and b are identical except for the C-
terminus, whereby HAVcR-1a is shorter than HAVcR-1b
and therefore missing the tyrosine phosphorylation motif
QAENIY (Fig. 1D) (Bailly et al., 2002). Genomic
analysis and analysis of the cDNA product revealed that
HAVcR-1a and b are splice variants (Bailly et al., 2002). 
The complexity of HAVcR-1 leads to variability in
protein size. The gene is expected to encode a 36kDa
protein however due to four possible N-glycosylation
sites, multiple possible O-glycosylation sites and
possible biotinylation, it can result in the mature protein
being approximately 100kDa as well as the immature
protein being 70kDa or 50kDa. Due to proteolytic
cleavage close to the TMD, a soluble ectodomain of
HAVcR-1 is produced which is 10kDa less that the
uncleaved protein, thus making it approximately 90kDa,
whereas the membrane attached cleaved product is only
14kDa (Bailly et al., 2002).
Function in cancer
There have been numerous studies into the
importance of HAVcR-1 in renal cell carcinoma (RCC).
RCC is the most common type of kidney cancer in adults
being responsible for approximately 80% of cases it is
frequently diagnosed late making fatality rates high. The
most common histological type of RCC, accounting for
75-80%, is clear cell RCC (ccRCC) (Cohen and
McGovern, 2005). HAVcR-1 has been found to be
overexpressed by 2-12 fold in 8/13 of ccRCC but
interestingly expression is decreased in benign
oncoytomas (Vila et al., 2004). 60% of ccRCC contain
duplications in chromosome 5 which has been mapped
to Ch5q22-31.1 which contains the gene locus of
HAVcR-1, possibly explaining the increased expression
of HAVcR-1 however transcriptional control, mRNA
processing, mRNA export and protein stability may also
contribute (Kaplan et al., 1996; Vila et al., 2004). Both
the chromosomal location and overexpression of
HAVcR-1 implicates it in the development of RCC and
it is now thought that HAVcR-1 may be a susceptibility
gene for RCC (Vila et al., 2004; Cuadros et al., 2013).
In 769-P and HK-2 kidney cell lines when
differentiation is blocked and reverted with phorbol 12-
myristate-13- acetate (PMA), HAVcR-1 expression is
elevated. Furthermore overexpression of HAVcR-1 via
transfection in 769-P cells resulted in the prevention of
differentiation of the proximal tubule-derived cells and
altered expression of other members of the family
associated with differentiation/ de-differentiation events,
suggesting HAVcR-1 is involved in the regulation of
these events (Vila et al., 2004). HAVcR-1 has also been
suggested to induce cell growth due overexpression and
silencing in 769-P cells resulting in an increased or
decreased proliferation index respectively (Cuadros et
al., 2014). In wound healing experiments, over-
expression of HAVcR-1 resulted in delayed migration
and increased migration when expression was decreased
(Cuadros et al., 2014). It may therefore be possible that
the regulation of HAVcR-1 expression is important for
multiple stages of cancer progression. 
Ig-like domains are implicated in mediating protein-
protein interactions at the cell surface especially cell-cell
and cell-extracellular matrix (Kozarsky et al., 1988). The
mucin domain which extends Ig-like domain away from
surface like a stalk could have a role in configuration
and protection as well as cell adhesion (Kozarsky et al.,
1988; Jentoft, 1990). It is also possible that similarly to
other cell surface mucins, such as MUC1, the mucin-like
domain of HAVcR-1 may act in an anti-adhesive manner
by preventing interactions between cells as well as
between cells and the extracellular matrix (Komatsu et
al., 1997; DeLoia et al., 1998). This may be a
mechanism to allow detachment of cancer cells from
primary tumours, a critical step in metastasis (Komatsu
et al., 1997).
HAVcR-1 may therefore be a novel target for
therapeutics in a variety of cancers and it has been
shown that the monoclonal antibody 190/4 (mAb 190/4)
binds HAVcR-1 and is internalized into the cell making
it ideal for generation of an immunotoxin either by its
conjugation with a toxin or its use in conjunction with a
secondary antibody conjugated with a toxin (Weltman et
al., 1987; Vila et al., 2004). The use of the mouse mAb
190/4 followed by a secondary anti-mouse antibody
conjugated to the toxin saporin was shown to effectively
kill the kidney cell line GL37 via the HAVcR-1 receptor,
making it a possible anti-cancer treatment (Vila et al.,
2004).
The HAVcR-1 ectodomain
Similarly to numerous integral plasma-membrane
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proteins, HAVcR-1 has a soluble form released into the
extracellular space produced by proteolytic cleavage
close to the TMD and cells expressing HAVcR-1b are
known to constitutively shed the ectodomain into the
extracellular space (Hooper et al., 1997; Bailly et al.,
2002). The cleavage of HAVcR-1 is predicted to be
mediated by metalloproteases of the matrix
metalloprotease (MMP) family or the a desintegrin and
metalloprotease (ADAM) family due to cleavage being
blocked by bitamastat (B4-94) and ilomastat (GM6001)
which are broad band spectrum hydroxamic acid based
zinc metalloprotease inhibitors. HAVcR-1 cleavage has
also been shown to be increased by PMA treatment
which is known to activate protein kinase C resulting in
the shedding of many membrane proteins mediated by
metalloproteases of the ADAM family. The cleavage site
has been predicted to occur between residues 266 to 278
due to an antibody targeting the TSH-rich region
blocking cleavage and due to shared homology in the
extracellular domain both HAVcR-1a and b are
equivalent substrates for proteases (Bailly et al., 2002;
Zhang et al., 2007). HAVcR-1 shedding is enhanced by
treatment with pervanadate, a protein tyrosine
phosphatase inhibitor, which activates p38 and ERK-
MAPK signaling. Inhibitors of p38 such as SB202190
blocked pervanadate induced shedding thus the ERK-
MAPK signaling pathway appears to be important for
HAVcR-1 shedding (Zhang et al., 2007).
Shedding of ectodomains has been reported in a
variety of adhesion molecules. The ectodomains of these
molecules have been found to regulate cell adhesion
either by being an antagonist for adhesion via down
regulation or competition, or promoting adhesion via the
ectodomain binding two cell surface and matrix
components (Lochter et al., 1997; Kahn et al., 1998).
Similarly to HAVcR-1, L1 is a type 1 membrane
glycoprotein of the immunoglobulin superfamily.
Proteolytic cleavage proximal to the plasma membrane
produces soluble L1 which has been found to mediate
cell migration by autocrine binding to ανβ5 integrins as
well as integrin-mediated adhesion (Beer et al., 1999;
Mechtersheimer et al., 2001). Although the effect of the
HAVcR-1 ectodomain on adhesion and migration has
not been fully investigated it has been shown that the Ig-
like domain mediates the binding of soluble HAVcR-1 to
a number of cell types. 
The HAVcR-1 ectodomain has been shown to
increase IL-6 expression which activates the STAT-3
pathway leading to increased HIF-1α (Fig. 2) (Cuadros
et al., 2014). High levels of IL-6 are present in patients
with metastatic renal cell carcinoma (RCC) and are
correlated with poor survival. IL-6 binds the ligand
binding receptor gp80 which leads to the
phosphorylation of tyrosine residues of the transducing
receptor gp130. This allows for the docking and
phosphorylation of the activator of transcription STAT-3
(Heinrich et al., 1998). STAT-3 transcriptionally
activates genes involved in tumour proliferation,
apoptosis inhibition and angiogenesis including HIF1α,
a key protein in promoting hypoxia induced
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Fig. 2. The HAVcR-1
Ectodomain. Adapted from
(Cuadros et al., 2014).
Showing HAVcR-1 activation of
the IL-6/ STAT-3 and
potentially regulates
angiogenesis as well as the
other potential functions of the
HAVcR-1 ectodomain.
angiogenesis (Jung et al., 2005).
HAVcR-1 shedding may therefore mediate
angiogenesis and metastasis by regulating adhesion,
migration and HIF-1α levels thus could be targeted as
therapeutic target. The production of soluble HAVcR-1
can be inhibited by small molecule inhibitors of
metalloproteases. However similarly to Herceptin
(Transtuzamab) blocking the proteolytic cleavage of
HER2 in breast cancer, therapeutic monoclonal
antibodies blocking the cleavage site of HAVcR-1 may
be a more specific therapeutic in HAVcR-1 positive
cancers (Molina et al., 2001; Bailly et al., 2002). 
Mortality rates of cancer can in part be attributed to
poor detection and screening methods. An example of
this is in RCC, especially in the subtype clear cell RCC
(ccRCC), where late presentation leads to high mortality
rates, thus highlighting the need for improved screening
techniques for this cancer. Radiological studies are not
able to reliably distinguish between benign renal
tumours and RCC and the use of such techniques for
early screening is impractical and costly (Han et al.,
2005; Millet et al., 2011). Percutaneous biopsies/fine
needle aspiration used to distinguish histology has risks
including; hemorrhage and tumour seeding along the
needle track, another major drawback is the requirement
of experienced cytopathologists which are not always
available, all of which decrease the amount these
procedures are performed (Lebret et al., 2007; Sahni et
al., 2011). 
Having previously been shown to be a biomarker of
a wide variety of acute and chronic kidney diseases and
the demand for a novel biomarker in RCC led to
investigation into the potential use of urinary HAVcR-1
(Han et al., 2005; Morrissey et al., 2011). Formed via the
shedding of HAVcR-1, urinary HAVcR-1 has the
potential to distinguish between benign renal tumours
and RCC as well as between ccRCC and other
histological types of RCC (Han et al., 2005; Shalabi et
al., 2013). There is also evidence that there is a
correlation between the amount of urinary HAVcR-1
detected and RCC tumour size and grade (Han et al.,
2005; Cuadros et al., 2013). The use of urinary HAVcR-
1 may therefore lead to highly informative non-invasive
testing. Low level of urinary HAVcR-1 have also been
found in prostate cancer thus urinary HAVcR-1 has the
potential to be a useful biomarker in other cancers as
well as RCC (Han et al., 2005). In cancers where the
HAVcR-1 ectodomain is not shed into the urine it may
be shed into the circulation enabling HAVcR-1 to be a
biomarker for other cancers. 
HAVcR-1 in tight junctions
The maintenance of distinct fluid compartments is
integral in multicellular organisms. These compartments
are established by endothelial and epithelial sheets
(Tsukita and Furuse, 1999). To enable the formation and
maintenance of the distinct composition of adjacent
tissue compartments the paracellular space between
epithelial/endothelial cells needs to be sealed to prevent
non-specific solute diffusion (Anderson and Van Itallie,
1995).To allow transport of molecules between different
compartments epithelial and endothelial cells must have
different protein compositions on basolateral and apical
membranes to allow for polarized transport (Tsukita and
Furuse, 1999). To accomplish this tight junctions (TJ)
seal the membranes of adjacent epithelial and
endothelial cells leading to the obliteration of the
intercellular space between these adjacent membranes
thus acting as a barrier against paracellular transport as
well as a fence to maintain apical and basolateral
composition (Farquhar and Palade, 1963; Rindler et al.,
1982; Giepmans and van Ijzendoorn, 2009). 
TJ consist of three components; integral trans-
membrane proteins, peripheral/ plaque anchoring
proteins and TJ associated/ regulatory proteins (Martin,
2014). Integral transmembrane proteins are essential
adhesion proteins responsible for the correct assembly of
TJ which is achieved by peripheral proteins, which act as
a scaffold binding TJ molecules together and linking
them to the actin cytoskeleton as well as signalling
mechanisms, alongside associated/ regulatory proteins
(Madara, 1987; Martin, 2014). Occludin, a 60kDa
integral membrane protein was the first integral
component of TJ to be identified (Furuse et al., 1993).
The claudin family were the next components of TJ to be
identified. Both claudin 1 and claudin 2 are 23kDa
integral membrane proteins with 38% identical amino
acid sequences to each other but no similarity to
occludin amino acid sequence, however structurally they
all contain 4 transmembrane domains (Furuse et al.,
1998). Currently 27 claudin family members have been
identified and alongside them and occludin other integral
transmembrane proteins include: tricellulin, marvelD3
and junctional adhesion molecules (JAMs) (Mineta et
al., 2011; Jiang et al., 2015). Numerous peripheral
membrane proteins have also been identified including:
zonula occludin-1 (ZO-1), ZO-2, ZO-3, cingulin, 7H6,
Rab3B and AF-6 (Haskins et al., 1998). ZO-1, ZO-2 and
ZO-3 are 225kDa, 160kDa and 130kDa respectively and
belong to the MAGUK family (Stevenson et al., 1986;
Jesaitis and Goodenough, 1994; Haskins et al., 1998).
ZO-3 has been found to interact with ZO-1 and occludin
and ZO-2 interacts with ZO-1 (Fig. 3) (Jesaitis and
Goodenough, 1994; Haskins et al., 1998). TJ are
therefore complex multiprotein structures and it is now
becoming clear that they are not just responsible for cell
polarity and blocking paracellular diffusion but also have
roles in other cellular processes such as proliferation and
differentiation as well as the prevention of metasastasis
(Latorre et al., 2005; Jiang et al., 2015). Over half of
patients have already progressed to metastatic disease at
time of diagnosis, thus tumour metastasis is the most life
threatening event for cancer patients (DeVita et al.,
1975). 
The process of metastasis is complex, requiring
numerous sequential events to successful, however it can
be broken down into three main steps: invasion,
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intravasation and extravasation. Invasion involves the
loss of cell to cell contact thus allowing to dissociation
of cancer cells leading to invasion of the surrounding
stoma. Surrounding blood vessels formed by
angiogenesis provide a route in which cancer cells can
be transported to distant sites in the body. Thus the
dissociated cancer cell must penetrate the endothelium to
enter the circulatory system (intravasation) as well as to
exit the circulatory system (extravasion) prior to forming
secondary and tertiary foci (Martin, 2014). TJ exist
between adjacent cancer cells in tumours of epithelia,
thus act to prevent cancer cell dissociation, as well as
existing between cells of endothelia, thus acting as a
barrier against the movement of cancer cells through
epithelia preventing intravasation and extravasation
(Martin et al., 2002; Martin and Jiang, 2009). 
A number of virus receptors have been found to be
associated with junctional structures including adherins
and tight junctions. Investigations into the association of
HAVcR-1 with junctional structures found via
immunoprecipitation, the 50kDa HAVcR-1 associates
with the C terminal of ZO-1 and to a lesser extent ZO-2
as well as the N-terminal of occludin and RhoC (Fig. 3)
(Martin et al., 2011; Martin, 2014). Due to the
importance of these molecules in tight junctions it is
possible that HAVcR-1 is also involved in the tight
junction complex in endothelial and epithelial cells.
Overexpression and knockdown analysis of HAVcR-1 in
HECV endothelial cells suggests the importance of
HAVcR-1 expression in the hepatocellular growth factor
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Fig. 3. Tight Junctions. Adapted from (Tsukita
and Furuse, 1999; Shin et al., 2006).
Representation of epithelial cells connected via
tight junctions with magnified representation of
molecular components of tight junctions shown
and component found to interact with HAVcR-1
indicated by red stars.
(HGF) mediated breakdown of TJ. This was shown by
decreased transepithelial resistance in HAVcR-1
overexpressed HECV cells in comparison to HAVcR-1
knockdown HECV cells when treated with HGF. Dual
immunofluorescence of HAVcR-1 and ZO-1 showed an
increased expression and concentrated disruption of ZO-
1 in cell-cell junctions in knockdown HECV cells in
comparison to wild type HECV cells when treated with
HGF. Therefore it appears likely that both HGF and
HAVcR-1 act on the same pathway responsible for the
integrity and maintenance of TJ (Martin, 2014).
Overexpression of HAVcR-1 in cells results in decreased
TJ, therefore HAVcR-1 overexpression in cancer is
likely to also result in decreased TJ which may mediate
metastasis. HAVcR-1 may therefore be a target for anti-
metastatic cancer therapies. 
Conclusions and perspectives
HAVcR-1 is a type I transmembrane glycoprotein
which exists in two splice variants known as HAVcR-1a
and HAVcR-1b consisting of 334 and 359 amino acids
respectively. The variation in size is due to HAVcR-1a
having a smaller cytoplasmic domain than HAVcR-1b,
the effect of which has not been investigated. Due to
homology in the extracellular domain both variant are
subject to metalloprotease cleaving releasing an
ectodomain, the amount of which correlates with the
amount of IL-6 expression. This therefore links HAVcR-
1 to angiogenesis via the IL-6/STAT-3/HIF-1α pathway.
HAVcR-1 has also been linked to metastasis via the
regulation of TJ preventing cancer cell dissemination,
intravasation and extravasation. Both processes are
critical for cancer development thus making HAVcR-1 a
potential target for cancer therapeutics however further
investigation to determine the functions of HAVcR-1 is
required. The HAVcR-1 ectodomain being present in the
urine of curtain cancer makes it a potential biomarker
however the accuracy of its use needs to be determined
as well as investigations into the use of HAVcR-1 as a
biomarker in other cancers.
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